Adeno-associated virus (AAV) specialist Voyager Therapeutics (Nasdaq: VYGR) has sold options on some of its novel capsids to Novartis (NOVN: VX).
The deal could be worth over $1.5 billion in milestones, plus sales, if all goes according to plan.
At first, Voyager will receive $54 million and a possible $37.5 million in exercise fees related to three initial targets.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze